Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
219
resultados
Última actualización
21/11/2025 [06:51:00]
Resultados 50 a 75 de 219
Resumen de: AU2023368775A1
Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol% of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.
Resumen de: CN120938907A
本发明属于生物医药技术领域，提出了一种载球姜酮自组装纳米药物、可溶性微针贴片及其制备方法和应用，载球姜酮自组装纳米药物包括质量比为1.5‑5：0.35‑1.4：10‑20的球姜酮、吲哚菁绿和聚合物mPEG‑PLA。本发明还提供了载球姜酮自组装纳米药物的制备方法。本发明还提供了一种可溶性微针贴片，包括上述载球姜酮自组装纳米药物，所述可溶性微针贴片包括贴片基底和设置于所述贴片基底表面的针头；所述针头由载球姜酮自组装纳米药物和可溶性基质材料制备而成。本发明提供的载球姜酮自组装纳米药物，具有抗肿瘤作用，可以用于治疗黑色素瘤，提高了球姜酮的溶解性和生物利用率。
Resumen de: CN120943786A
本发明涉及一种可电离脂质化合物、相应的脂质纳米颗粒及其应用。本发明的可电离脂质化合物含有哌嗪结构和多条烷基链，在兼顾递送效率和靶向性的同时，降低毒副作用，便于大剂量和重复给药。该可电离脂质化合物及其脂质纳米颗粒可应用于递送小分子化药和各种核酸药物（siRNA、DNA、mRNA、miRNA，ASO等等）。
Resumen de: CN120939190A
本发明涉及中药组合物技术领域，提供了一种超级纳米包裹技术治疗男性勃起障碍的组合物及其制备方法，制备步骤如下：将刺蒺藜提取物、南非醉茄提取物、L‑精氨酸、东革阿里提取物、喜来芝提取物、葛缕子提取物、葛根提取物、牛蒡根提取物、火麻仁肽和超纯水、乙醇混合，得到混合物；将明胶和壳聚糖用超纯水溶解，得到壁材溶液；将混合物和壁材溶液混合，加入表面活性剂，搅拌，干燥，得到纳米包裹颗粒；将纳米包裹颗粒用胶囊填充机填充，得到组合物。本发明通过纳米包裹技术制备的组合物能够提高药物的稳定性和生物利用度；同时组合物中的各中药成分相互配伍，提升了精子活力和肾脏动力，增强了机体的抗疲劳能力，进而起到治疗性功能障碍的作用。
Resumen de: WO2024203660A1
The present invention provides a method for producing nucleic acid-encapsulated lipid nanoparticles, the method comprising the following steps (a) and (b): (a) a step for mixing an alcohol solution containing an ionic lipid having a tertiary amino group, a sterol and a PEG lipid with a citrate buffer solution, in which a nucleic acid is dispersed and which has a pH of 3-6.5, to prepare a suspension of nucleic acid-encapsulated lipid nanoparticles; and (b) a step for concentrating the suspension of the nucleic acid-encapsulated lipid nanoparticles by ultrafiltration and diluting the suspension with a tris buffer solution having a pH of 5.2-9.0 to thereby replace the dispersion medium of the suspension with the tris buffer solution.
Resumen de: WO2024205076A1
The present invention relates to a device useful for manufacturing nanoparticles that contain hydrophobic and hydrophilic substances. Specifically, the device according to the present invention is characterized by comprising: a plurality of inlet channels through which the hydrophobic and hydrophilic substances respectively flow; a mixing channel in which the substances are mixed to manufacture the nanoparticles; and an outlet channel through which the manufactured nanoparticles flow out, wherein the mixing channel includes micro-pillars that can increase the mixing efficiency of the substances. Therefore, the nanoparticles manufactured using the device according to the present invention exhibit excellent particle uniformity and can be useful as drugs or drug delivery carriers.
Resumen de: WO2024220043A1
The present disclosure relates to a composition for prohibiting cross-species infection of malaria caused by P. vivax in a subject. Preferably, the disclosed composition is prepared in the form of a vaccine, which comprises a plurality of polynucleotides each comprising a sequence as setting forth in SEQ ID No. 1 or SEQ ID No. 2, the polynucleotides being expressed in a body of the subject for inducing an immune response reactive against the infection of malaria thereof; a liquid phase of lipid nanoparticles configured to form a protective layer encapsulating the pluralities of polynucleotides within the protective layer; and a pharmaceutically acceptable adjuvant.
Resumen de: WO2024026029A2
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Resumen de: CN120938870A
本发明属于化妆品原料技术领域，尤其涉及一种积雪草发酵微囊及其制备方法与应用。本发明将药用植物积雪草用多元醇溶解进行发酵，且发酵前后不进行高压蒸汽灭菌，保留更多活性成分，提高原料中具有舒缓修复功效的羟基积雪草苷等活性成分的溶解度，同时通过微射流对羟基积雪草苷等活性成分进行包裹并形成微囊，增加活性成分的水溶性和稳定性，确保活性成分能被皮肤有效吸收。本发明的微囊中包裹了积雪草中具有舒缓修复功效的活性成分形成纳米粒，实现高效舒缓修复功效的同时，更加稳定、安全无刺激；且微囊成分简单，不含有致敏性成分，安全性高。
Resumen de: CN120943972A
本发明涉及分子生物学技术领域，公开了一种新型自包封MVP‑INT纳米蛋白颗粒及其应用。本发明一种新型自包封MVP‑INT纳米蛋白颗粒，其是由MVP基因、自切割内含体基因和INT基因串联而成。本发明提供的一种新型自包封MVP‑INT纳米蛋白颗粒，通过自切割内含肽将MVP纳米颗粒与INT蛋白设计在一起，制备出可以自我封装药物的蛋白纳米颗粒，降低使用纳米颗粒进行封装药物的繁琐过程，优化MVP作为纳米载体的使用问题和挑战，提高纳米载体的包封药物的效率，为通用性纳米颗粒载体的研发提供市场价值。
Resumen de: CN120939138A
本发明公开了复方佛手柑鼻腔洗液及其应用，属于医药技术领域。本发明通过将佛手柑素，丙酮酸钠，金银花提取物与淡竹叶多糖结合，佛手柑素能够抑制病毒刺突蛋白与ACE2结合，丙酮酸钠能够阻断病毒ROS信号通路，金银花提取物能够抗炎抑菌，本发明通过上述物质的组合，实现了“物理冲洗+药物渗透”双重机制，能够降低病毒载量，所得复方佛手柑鼻腔洗液的实现了协同增效的效果，抗病毒和抗炎效果显著优于单一成分洗液。
Resumen de: WO2024102746A1
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
Resumen de: WO2024102965A1
Disclosed herein are designer extracellular vesicles (EVs) that target muscle cells. For example, in some embodiments, the EVs are decorated NHERF1, NHERF2, a fusion protein containing an E8 fragment of laminin and an exosomal or lysosomal transmembrane protein, or a combination thereof. These EVs can in some embodiments, be used to deliver diagnostic and/or therapeutic cargo to muscle cells in a subject in need thereof. In some embodiments, these EVs are loaded with a DUX4 silencing oligonucleotide to treat Facioscapulohumeral muscular dystrophy (FSHD) in a subject. For example, in some embodiments, the therapeutic cargo is a DUX4 silencing oligonucleotide.
Resumen de: AU2023375482A1
Bioadhesive biodegradable polymeric nanoparticles can be administered intrathecally into the spinal column, for example, through the cisterna magna, for dissemination for the treatment of tumors such as leptomeningeal metastasis. The nanoparticles rapidly spread to all central spinal fluid (CSF) compartments, including the brain parenchyma and spinal column. The bioadhesive nanoparticles penetrate and are retained for long periods, during which they can continue to release agents. These nanoparticles can be loaded with different therapeutic, prophylactic or diagnostic agent, most preferably DNA-repair inhibitor drugs to enhance killing of leptomeningeal tumors like leptomeningeal metastasis and seeding tumors such as medulloblastoma. In a preferred embodiment, the patients are treated with a combination of a PARP inhibitor and temozolomide.
Resumen de: CN120456930A
The present invention provides targeted polymer complexes comprising: (i) a nucleic acid, in particular a nucleic acid encoding a peptide or protein having pharmaceutical activity; and (ii) a targeting conjugate comprising LPEI and PEG fragments linked by discrete bonds formed by a defined chemically selective reaction. Thus, the LPEI fragment is bonded to a single PEG fragment in a linear end-to-end manner. The linear conjugate is further conjugated to a targeting fragment to achieve selective interaction with a particular cell type. The polymer complexes selectively deliver nucleic acids to target cells, thereby achieving high expression and efficient protein translation and secretion of the encoded pharmaceutically active proteins.
Resumen de: CN120302964A
The invention discloses a targeting nanoscale particle, a targeting cell as well as a preparation method and application of the targeting nanoscale particle and the targeting cell. Wherein the outer surface of the targeting cell is combined with a targeting nano-scale particle, the targeting nano-scale particle is formed by mutually connecting a plurality of proteins through a first combination part, the targeting nano-scale particle further comprises a second combination part, and the targeting nano-scale particle is combined with the outer surface of the target cell through the second combination part. In an exemplary embodiment, the targeting nanoscale particles can promote interaction between the chimeric antigen receptor T cells and the leukemia cells by being simultaneously combined with the chimeric antigen receptor T cells and the leukemia cells, and then the chimeric antigen receptor T cells are promoted to recognize and kill the leukemia cells. In addition, a space is provided for loading of chemotherapeutic drugs by a protein internal cavity in the targeting nanoscale particles, and combined therapy of the chimeric antigen receptor T cells and other therapies is realized while the drugs are loaded.
Resumen de: CN120475962A
The present disclosure relates to particulate compositions, such as liposomes and lipid nanoparticles, comprising polysarcosine-lipid conjugates, as well as methods of making and using the same.
Resumen de: WO2025235925A1
Disclosed are compounds and compositions that preferentially target cancer cells with a warhead that comprises a chemotherapeutic agent releasably bound to a targeting agent where the chemotherapeutic agent is released upon cellular absorption. Also disclosed are methods of use.
Resumen de: AU2025256158A1
A method for reducing postprandial glucose from a meal includes orally administering to an individual a composition containing whey protein micelles (WPM) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the WPM and within about one hour of the oral administration of the composition containing the WPM. For example, the meal can be administered about thirty minutes after the administration of the composition containing the WPM. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising whey protein isolate. A method for reducing postprandial glucose from a meal includes orally administering to an individual a composition containing whey protein micelles (WPM) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the WPM and within about one hour of the oral administration of the composition containing the WPM. For example, the meal can be administered about thirty minutes after the administration of the composition containing the WPM. The postprandial glucose is reduced relative to postprandial glucose from administering a corresponding composition comprising whey protein isolate. ct c t
Resumen de: WO2025235336A1
Disclosed herein are drug delivery vehicle compositions, comprising lipid nanoparticle-forming molecules, a nitric oxide donor (NO-donor) molecule, and a hydrogel. Also disclosed are methods of making the same by mixing the lipid nanoparticle- forming molecules and the NO-donor in a hydrophobic solvent to form a first mixture; and adding a mixture of hydrogel and water, and optionally a buffer solution, to the first mixture to form the drug delivery vehicle composition. In addition, disclosed herein are methods of treating a patient suffering from a disease that can be treated with nitric oxide, the method comprising identifying a patient in need thereof, and administering to the patient a drug delivery vehicle disclosed herein.
Resumen de: WO2025235378A2
Provided herein are protein complexes comprising lipid nanoparticles and bispecific antibody constructs, wherein the lipid nanoparticles comprise a cargo. Also provided are protein complexes comprising lipid nanoparticles, bispecific antibody constructs, and antibodies, wherein the lipid nanoparticles comprise a cargo. The protein complexes disclosed herein are useful, for example, for delivering the cargo to a cell or a tissue of interest.
Resumen de: CN115279418A
The present invention provides, inter alia, methods and compositions for selectively degrading proteins. In some aspects, a messenger RNA (mRNA) encoding a ubiquitin pathway moiety and a binding peptide that binds to a target protein is described, where the mRNA is encapsulated within a lipid nanoparticle. Also provided herein are mRNA encoding at least two binding peptides wherein a first binding peptide binds to an ubiquitin pathway moiety and a second binding peptide binds to a target protein, and wherein the mRNA is encapsulated within a lipid nanoparticle.
Resumen de: WO2025234591A1
The present invention relates to an antibody-drug conjugate binding to Nectin-2 and use thereof, in which a mouse monoclonal antibody (m12G1 clone) and a chimeric anti-Nectin-2 antibody (chimeric 12G1; c12G1), which are capable of specifically targeting Nectin-2, have been prepared. The c12G1 antibody specifically bound to the C2 domain of human Nectin-2 with high affinity, but did not bind to mouse Nectin-2. Subsequently, an antibody-drug conjugate comprising a c12G1 antibody conjugated to DM1 was prepared, and as a result of examining the cytotoxic effect thereof on cancer cells in vitro and in vivo, c12G1-DM1 induced cell cycle arrest in the mitotic stage of Nectin-2-positive ovarian cancer cells, but not in Nectin-2-negative cancer cells. c12G1-DM1 induced approximately 100-fold cytotoxicity at IC50 in the range of 0.1-7.4 nM in ovarian cancer cells as compared to normal IgG-DM1, and c12G1-DM1 exhibited approximately 91% tumor growth inhibition in a mouse xenograft model transplanted with OV-90 cells. These results suggest that c12G1-DM1 can be effectively used as a potential therapeutic agent for Nectin-2-positive ovarian cancer.
Resumen de: WO2025234761A1
The present invention relates to an automated apparatus for producing nanoparticles, and a nanoparticle production method using same. Specifically, the present invention relates to the automated apparatus for producing nanoparticles, comprising: a microfluidic device; a mounting part for fastening the microfluidic device to the automated apparatus; an inlet part that supplies a fluid containing raw materials; a pneumatic pressure control part that provides pressure for fluid movement; and a recovery part that recovers the produced nanoparticles according to the condition thereof.
Nº publicación: WO2025234961A1 13/11/2025
Solicitante:
ISTANBUL UNIV CERRAHPASA REKTORLUGU [TR]
ISTANBUL UNIVERSITESI - CERRAHPASA REKTORLUGU
Resumen de: WO2025234961A1
The present invention relates to the clay based nano drug delivery system and production method thereof. In the method of the present invention, supercritical carbon dioxide extraction (SCCO2) is used to increase the bioavailability of all kinds of hydrophobic, i.e. water-insoluble, active substances. The present invention is used in the chemical industry, pharmaceutical industry and food industry to increase the solubility of the any compound after oral administration, increase its absorption in the blood and/or ensure its slow release in the blood.
BOPI
Sede Electrónica
